Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

HCM is inherited as a mendelian autosomal dominant trait and caused by mutations in any one of 11 genes, each encoding proteins of the cardiac sarcomere. It has an incidence of 1 in 500 of the general ...

Numerous motor and structural proteins compose a highly ordered structure known as the sarcomere, the basic unit of muscle contraction in heart and skeletal muscles. Sarcomeric myosin heavy chain ...

He will now lead the development of EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, along with the company's cardiovascular and cardiometabolic pipeline. Dr. Derakhshan ...

Staining indicates cardiac sarcomere proteins alpha actinin and cardiac troponin T, in addition to nuclear stain DAPI. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news ...

EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team ...